权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Stabilization of Glucagon by Trehalose Gylcopolymer Nanogels

海藻糖乙二醇聚合物纳米凝胶对胰高血糖素的稳定性

基本信息

批准号：
10558471
负责人：
Heather D Maynard
金额：
$ 38.05万
依托单位：
UNIVERSITY OF CALIFORNIA LOS ANGELES
依托单位国家：
美国
项目类别：
财政年份：
2021
资助国家：
美国
起止时间：
2021-04-01 至 2025-01-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10558471
关键词：
Acidity Address Amyloid Animals Antibodies Biochemistry Biodistribution Biological Assay Biological Availability Biophysics Blood Glucose Cell Culture Techniques Cellular Assay Cessation of life Charge Chemicals Chemistry Coma Crosslinker Dangerousness Detection Diabetes Mellitus Disease Disulfides Dizziness Dose Drug Delivery Systems Drug Kinetics Dryness Encapsulated Endocrinology Excretory function Exposure to FDA approved Fiber Formulation Foundations Free Radicals Gel Generations Glucagon Glucose Goals Hepatocyte Hormones Hour Human Hypertension Hypoglycemia Immune response In Situ In Vitro Inflammatory Response Injections Insulin Insulin-Dependent Diabetes Mellitus Investigation Lipopolysaccharides Liver Longitudinal Studies Measures Medicine Methacrylates Molecular Mus NanoGel Nature Organic solvent product Ovalbumin Pain Pathway interactions Patients Peptides Perfusion Phase Polymers Positron-Emission Tomography Powder dose form Proteins Reagent Refrigeration Safety Saline Seizures Signal Transduction Site Solid System Techniques Temperature Testing Therapeutic Time Tissues Trehalose Validation Vision Work acute toxicity aged aqueous biomaterial compatibility counterregulation crosslink cytokine diabetic patient ethylene glycol experience experimental study in vivo insulin tolerance nanoparticle nanosized novel therapeutics peptide drug peptide hormone polymerization professor receptor response side effect success sugar tool

项目摘要

Project Summary Glucagon interacts with receptors in the liver to raise glucose levels. Normally glucagon is released endogenously. Yet for some diseases such as Type I diabetes, hypoglycemia defined as blood glucose level below 70 mg/dL occurs in a large number of patients. Hypoglycemia has side effects ranging from dizziness and shakiness, to blurry vision and seizures, to coma and death. To treat this potentially fatal condition, glucagon is administered via injection. However, glucagon is typically inactivated in solution within hours, forming amyloid- like fibers that are toxic and potentially dangerous for patients. This necessitates a complicated injection system wherein the peptide is kept as a dry powder and dissolved in acidic pH right before use. The acidity of the formulation causes pain at the injection site. A recently approved formulation circumvents this issue, but instead utilizes organic solvent, which is undesirable. Recently the PI discovered bioresponsive nanogels that stabilize glucagon in neutral solution for at least three weeks and maintain glucagon bioactivity. Nanogels containing a sugar stabilizer found in Nature, trehalose, were synthesized utilizing glucagon as the cross-linker. Under mildly reductive conditions the glucagon was released. Released glucagon and the glucagon nanoparticles were bioactive. This work is important because it suggests that trehalose nanogels can be utilized to stabilize glucagon in neutral solution and release active peptide when needed. Herein, it is proposed to build upon this foundation to prepare a new formulation for the stabilization and delivery of glucagon. Specifically, it is hypothesized that trehalose nanogels will stabilize glucagon in aqueous solutions and at room temperature, will release active glucagon and be safe and non-immunogenic in vivo. To test this hypothesis and meet the objectives, three specific aims are proposed. The first is to develop uniform sized nanogels and evaluate the long term stability of glucagon in the nanoparticle formulation. The achieve this, poly(methacrylate trehalose-co-pyridyl disulfide methacrylate) will be synthesized and cross-linked with bisthiolated poly(ethylene glycol). Glucagon will be loaded by covalent and physical encapsulation to form uniform gels. The resulting glucagon nanogels will be characterized and studied for long term solution and solid phase stability. Standard tests to observe aggregation of the glucagon and nanoparticles and chemical changes of the glucagon will be undertaken. Second will be to investigate in vitro and in vivo efficacy and bioavailability of glucagon nanogels. Standard cellular assays will be utilized to determine activity. Then an in situ liver perfusion assay will assess perfusate glucose concentrations upon exposure to the nanogels and allow for molecular signaling validation. Glucose counterregulation during insulin tolerance test will validate activity in whole animals. The third aim will be to determine in vivo safety of the nanoparticle formulation. Specifically, acute toxicity, biodistribution, excretion, pharmacokinetics, antibody generation and cytokine response to the nanogels will be tested in mice. This work is aligned with the long-term goal to provide new therapeutic tools to safely and effectively manage glucose levels for Type I diabetes patients.

项目摘要胰高血糖素与肝脏中的受体相互作用以提高葡萄糖水平。正常情况下，胰高血糖素内生的然而，对于一些疾病，如I型糖尿病，低血糖定义为血糖水平低于70 mg/dL的情况发生在大量患者中。低血糖会产生副作用，颤抖，视力模糊，癫痫，昏迷和死亡。为了治疗这种潜在的致命疾病，胰高血糖素通过注射给药。然而，胰高血糖素通常在溶液中在数小时内失活，形成淀粉样蛋白- 比如有毒的纤维对病人有潜在的危险。这需要复杂的喷射系统其中所述肽保持为干粉并在临用前溶解于酸性pH。的酸度制剂引起注射部位疼痛。最近批准的一种配方规避了这个问题，使用有机溶剂，这是不希望的。最近PI发现了生物反应纳米凝胶，胰高血糖素在中性溶液中至少三周并保持胰高血糖素生物活性。纳米凝胶含有利用胰高血糖素作为交联剂合成了天然存在的糖稳定剂海藻糖。在轻度在还原条件下，胰高血糖素被释放。释放的胰高血糖素和胰高血糖素纳米颗粒是生物活性的这项工作很重要，因为它表明海藻糖纳米凝胶可用于稳定胰高血糖素并在需要时释放活性肽。在此，建议在此基础上再接再厉，以制备用于稳定和递送胰高血糖素的新制剂。具体而言，假设海藻糖纳米凝胶将稳定水溶液中的胰高血糖素，并且在室温下将释放活性物质，胰高血糖素，并且在体内是安全的和非免疫原性的。为了验证这一假设并达到目标，提出了具体目标。首先是开发均匀尺寸的纳米凝胶并评估长期稳定性的胰高血糖素。实现这一点，聚（甲基丙烯酸酯海藻糖-co-吡啶基二硫化物甲基丙烯酸酯）将被合成并与双硫醇化的聚（乙二醇）交联。胰高血糖素将是通过共价和物理包封负载以形成均匀的凝胶。所得的胰高血糖素纳米凝胶将是表征并研究了长期溶液和固相稳定性。观察聚集的标准试验将进行胰高血糖素和纳米颗粒的组合以及胰高血糖素的化学变化。第二，研究胰高血糖素纳米凝胶体外和体内功效和生物利用度。标准细胞分析将是用于确定活动。然后原位肝脏灌注测定将评估灌注液葡萄糖浓度在暴露于纳米凝胶时，并允许分子信号传导验证。葡萄糖反调节胰岛素耐受性试验将验证整个动物的活性。第三个目的是确定在体内的安全性，纳米颗粒制剂。具体而言，急性毒性、生物分布、排泄、药代动力学、抗体将在小鼠中测试纳米凝胶的产生和细胞因子应答。这项工作符合长期目的是提供新的治疗工具，以安全有效地管理I型糖尿病患者的血糖水平。